A Phase II Study of Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
Phase of Trial: Phase II
Latest Information Update: 20 May 2017
At a glance
- Drugs Leuprorelin (Primary) ; Palifermin (Primary)
- Indications Immunosuppression
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 18 May 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 18 May 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.